KidneyGenRx (101212591)

  https://cordis.europa.eu/project/id/101212591

  Horizon Europe (2021-2027)

  Developing RNA-editing based therapy for renal cystic ciliopathies

  ERC PROOF OF CONCEPT GRANTS (ERC-2024-POC)

  mutation

  2025-05-01 Start Date (YY-MM-DD)

  2026-10-31 End Date (YY-MM-DD)

  € 0 Total Cost

  Description

Chronic Kidney Disease (CKD) is a significant global health burden, affecting approximately 10% of the adult population worldwide. It is estimated that 10-20% of advanced CKD cases are caused by genetic kidney diseases, with renal cystic ciliopathies being the most common genetic contributors. In the Israeli Druze population, we have identified a novel homozygous mutation in the WDR19 gene as the leading cause of end-stage kidney disease (ESKD), particularly leading to renal failure in young adults. Currently, kidney failure caused by renal cystic ciliopathies can only be treated through renal replacement therapies, such as dialysis or transplantation, as no specific therapeutic interventions are available. This project aims to establish proof of concept that RNA editing can serve as a viable therapeutic strategy for genetically driven kidney failure. By employing Site-Directed RNA Editing (SDRE) through the action of Adenosine Deaminase Acting on RNA (ADAR) enzymes, we aim to correct the pathogenic WDR19 mutation (c.878G>A) at the RNA level. Our efforts will focus on optimizing guide RNA (gRNA) design and improving delivery mechanisms to maximize editing efficiency and therapeutic outcomes. The efficacy of this approach will be evaluated by its ability to rescue the disease phenotype in patient-derived induced pluripotent stem cell (iPSC)-derived kidney organoids and further validated in murine models. If successful, this proof-of-concept project could pave the way for RNA editing-based therapies as a transformative treatment for genetic kidney diseases.

  Complicit Organisations

1 Israeli organisation participates in KidneyGenRx.